BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares. ・The update followed the ...

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update ...

The technical backdrop, however, points to caution. Seeking Alpha's momentum page flags Moderna as overbought on its relative strength index, with RSI levels indicating the stock has sprinted ahead of ...

Moderna and Merck previously reported five-year follow-up data from their Phase 2b KEYNOTE-942 trial, showing that the ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b ...

Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

The vaccine maker is expanding beyond its COVID-focused offerings.

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...